CA2186783A1 - Preparations pharmaceutiques et substances medicinals pour la prevention et le traitement d'un dysfonctionnement endothelial - Google Patents

Preparations pharmaceutiques et substances medicinals pour la prevention et le traitement d'un dysfonctionnement endothelial

Info

Publication number
CA2186783A1
CA2186783A1 CA002186783A CA2186783A CA2186783A1 CA 2186783 A1 CA2186783 A1 CA 2186783A1 CA 002186783 A CA002186783 A CA 002186783A CA 2186783 A CA2186783 A CA 2186783A CA 2186783 A1 CA2186783 A1 CA 2186783A1
Authority
CA
Canada
Prior art keywords
compounds
endothelial
nitrogen monoxide
release
dysfunctions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002186783A
Other languages
English (en)
Inventor
Eike Albrecht Noack
Georg Kojda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Puren Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2186783A1 publication Critical patent/CA2186783A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur l'utilisation de composés qui libèrent ou transfèrent du monoxyde d'azote, de stimulateurs de formation de monoxyde d'azote endogène et de stimulateurs de la guanylatcyclase pour la prévention, le traitement et l'élimination de dysfonctionnements endothéliaux ou de maladies associées à ces dysfonctionnements ou causées par ceux-ci. L'invention porte aussi sur l'utilisation desdits composés pour la préparation de produits pharmaceutiques dans les domaines d'application en question.
CA002186783A 1994-03-30 1995-03-28 Preparations pharmaceutiques et substances medicinals pour la prevention et le traitement d'un dysfonctionnement endothelial Abandoned CA2186783A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4410997.0 1994-03-30
DE4410997A DE4410997A1 (de) 1994-03-30 1994-03-30 Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
PCT/DE1995/000421 WO1995026725A1 (fr) 1994-03-30 1995-03-28 Preparations pharmaceutiques et medicaments pour la prevention et le traitement d'un dysfonctionnement endothelial

Publications (1)

Publication Number Publication Date
CA2186783A1 true CA2186783A1 (fr) 1995-10-12

Family

ID=6514213

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186783A Abandoned CA2186783A1 (fr) 1994-03-30 1995-03-28 Preparations pharmaceutiques et substances medicinals pour la prevention et le traitement d'un dysfonctionnement endothelial

Country Status (19)

Country Link
EP (1) EP0752858A1 (fr)
JP (1) JPH09510979A (fr)
CN (1) CN1150387A (fr)
BG (1) BG63073B1 (fr)
CA (1) CA2186783A1 (fr)
CZ (1) CZ283696A3 (fr)
DE (2) DE4410997A1 (fr)
EE (1) EE9600139A (fr)
FI (1) FI963883A7 (fr)
HU (1) HU220165B (fr)
IS (1) IS4365A (fr)
LT (1) LT4310B (fr)
LV (1) LV11666B (fr)
MX (1) MX9604434A (fr)
NO (1) NO964102L (fr)
PL (1) PL316528A1 (fr)
SI (1) SI9520047A (fr)
SK (1) SK121896A3 (fr)
WO (1) WO1995026725A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
DE19654895C2 (de) * 1996-02-07 2000-07-27 Sanol Arznei Schwarz Gmbh Detektionsverfahren
DE19604361C2 (de) * 1996-02-07 1999-01-14 Sanol Arznei Schwarz Gmbh Verwendung gasdichter Primärpackmittel für pharmazeutische Zusammensetzungen
DE19726812A1 (de) * 1997-06-25 1999-01-07 Isis Pharma Gmbh Neue Derivate des Pentaerythrits, deren Herstellung und Verwendung sowie Intermediate zur Synthese derselben
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
ZA989356B (en) * 1997-10-16 1998-11-16 Isis Pharma Gmbh Pharmaceutical preparations
DE19745622A1 (de) * 1997-10-16 1999-04-22 Isis Pharma Gmbh Neue Salpetersäureester des Pentaerythrits
KR100523112B1 (ko) * 1997-10-17 2005-10-19 유로진 리미티드 레닌-안지오텐신계 억제제의 사용
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU5503199A (en) * 1998-06-24 2000-01-10 Alpharma-Isis Gmbh And Co. Kg Analytic substrates and antioxidative agents
WO2001017528A1 (fr) 1999-09-08 2001-03-15 Nitromed, Inc. Methodes de traitement et de prevention de l'insuffisance cardiaque au moyen de composes d'hydralazine et de dinitrate d'isosorbide ou de mononitrate d'isosorbide
US6635273B1 (en) 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
US20100144864A1 (en) * 2007-04-05 2010-06-10 Ironwood Pharmaceuticals, Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
KR20140019004A (ko) * 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
RU2467748C1 (ru) * 2011-08-08 2012-11-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
JP5360939B2 (ja) * 2011-09-28 2013-12-04 国立大学法人徳島大学 ニトロソニフェジピン誘導体を有効成分とする動脈硬化症治療剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR984523A (fr) * 1949-02-10 1951-07-06 Phosphate de trinitro-triéthanolamine et procédé de préparation
DE1695897C3 (de) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-Acyl-sydnonimine, deren Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU465217B2 (en) * 1971-04-29 1975-09-18 American Home Products Corporation Mononitrte esters of 1,4:3, 6-dianhydro-d-glucitol
US3886186A (en) * 1971-04-29 1975-05-27 American Home Prod Mononitrate esters of 1,4:3,6-dianhydro-d-glucitol
DE2532124C3 (de) * 1975-07-18 1979-04-19 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von 4-Amino-morpholin
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
DE2623800C3 (de) * 1976-05-28 1978-11-23 Sanol Schwarz-Monheim Gmbh, 4000 Duesseldorf Obersättigte wässerige Isosorbiddinitrat-Lösung, Herstellungsverfahren und Verwendung
US4065488A (en) * 1977-02-24 1977-12-27 American Home Products Corporation Process for preparing 1,4:3,6-dianhydro-D-glucitol 2-nitrate
DE2903927C2 (de) * 1979-02-02 1981-03-12 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Verfahren zur selektiven Herstellung von Isosorbid-5-nitrat
DE3028873C2 (de) * 1980-07-30 1983-10-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von 1,4 zu 3,6-Dianhydro-D-glucit-5-nitrat (Isosorbid-5-nitrat)
DE3102947A1 (de) * 1981-01-29 1982-09-02 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-5-nitrat
FR2500835A1 (fr) * 1981-02-27 1982-09-03 Poudres & Explosifs Ste Nale Procede de synthese des mononitrates d'isosorbide
DE3117612A1 (de) * 1981-05-05 1982-11-25 Cassella Ag, 6000 Frankfurt Verfahren zur herstellung von isosorbid-5-nitrat
DE3124410A1 (de) * 1981-06-22 1983-01-05 Heinrich Mack Nachf., 7918 Illertissen Verfahren zur herstellung von isosorbid-2-nitrat
JPS5910513A (ja) * 1982-07-12 1984-01-20 Nitto Electric Ind Co Ltd 医薬製剤
DE3325652A1 (de) * 1983-07-15 1985-01-24 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Feste, stabile isosorbid-5-mononitrat enthaltende arzneimittelzubereitungen und verfahren zu ihrer herstellung
DE3328094A1 (de) * 1983-08-04 1985-02-21 H. Trommsdorff GmbH & Co, 5110 Alsdorf Phlegmatisierte pharmazeutische zubereitung von explosionsfaehigen salpetersaeureestern
EP0143507B1 (fr) * 1983-11-25 1989-09-20 TOSHIN CHEMICAL CO., Ltd. Procédé pour la préparation de nitrate-5 d'isosorbide et sel de sodium d'hydrate de nitrate-5 d'isosorbide comme précurseur de celui-ci
DD244980A1 (de) * 1985-12-18 1987-04-22 Isis Chemie Zwickau Veb Verfahren zur herstellung von n-morpholinoaminoacetonitril und dessen hydrochlorid
DD293492A5 (de) * 1987-11-26 1991-09-05 Isis-Chemie Gmbh,De Verfahren zur herstellung einer glyceroltrinitrat-arzneiform mit gleichmaessig verzoegerter arzneistofffreisetzung
US5284872A (en) * 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
DE4007705C1 (fr) * 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4038203A1 (de) * 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia

Also Published As

Publication number Publication date
AU2134595A (en) 1995-10-23
CZ283696A3 (cs) 1998-03-18
BG100930A (bg) 1997-07-31
LV11666B (en) 1997-06-20
FI963883L (fi) 1996-09-27
SI9520047A (en) 1997-06-30
CN1150387A (zh) 1997-05-21
NO964102D0 (no) 1996-09-27
NO964102L (no) 1996-09-27
LV11666A (lv) 1997-02-20
IS4365A (is) 1996-09-25
AU698359B2 (en) 1998-10-29
LT4310B (lt) 1998-03-25
EE9600139A (et) 1997-04-15
DE19580261D2 (de) 1997-05-28
HU220165B (hu) 2001-11-28
PL316528A1 (en) 1997-01-20
JPH09510979A (ja) 1997-11-04
HU9602671D0 (en) 1996-11-28
FI963883A0 (fi) 1996-09-27
DE4410997A1 (de) 1995-10-26
BG63073B1 (bg) 2001-03-30
WO1995026725A1 (fr) 1995-10-12
FI963883A7 (fi) 1996-09-27
LT96148A (en) 1997-12-29
EP0752858A1 (fr) 1997-01-15
SK121896A3 (en) 1998-10-07
HUT76676A (en) 1997-10-28
MX9604434A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
CA2186783A1 (fr) Preparations pharmaceutiques et substances medicinals pour la prevention et le traitement d'un dysfonctionnement endothelial
US5284867A (en) NMDA-blocking pharmaceutical compositions
KR101636395B1 (ko) 허혈 및 허혈 재관류 손상을 치료하기 위한 조성물 및 방법
EP1212081B2 (fr) Utilisations de ramipril pour prevenir l'insuffisance cardiaque globale
CA2483998A1 (fr) Composes derives de dicetohydrazine et medicaments contenant ces composes comme ingredient actif
PL195529B1 (pl) Zastosowanie inhibitora peptydazy dipeptydylowej IV
CA2372785A1 (fr) Composition pharmaceutique contenant des antagonistes de l'angiotensine ii et des inhibiteurs de l'enzyme de conversion de l'angiotensine i
JP2024041835A (ja) 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法
WO1996022774A2 (fr) Association medicamenteuse comprenant une sesquiterpene lactone et des vitamines du complexe b, destinee au traitement de la migraine et d'autres troubles
TWI223651B (en) Phosphonic acid derivatives having inhibitory activity against carboxypeptidase B
JPH0338520A (ja) うつ病の抑制治療剤
US20030087911A1 (en) Methods and compositions for treating hypertension
RS20050618A (sr) Upotreba dipiridamola u kombinaciji sa acetilsalicilnom kiselinom i antagonistom angiotenzina ii za prevenciju moždanog udara
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
TWI281858B (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
LeJemtel et al. Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction
Linz et al. Cardiac inhibition of angiotensin converting enzyme: role of kinins
CN109303778B (zh) 小檗碱在降低硝酸酯类药物耐药性中的应用
WO2004098611A1 (fr) Stimulant
IE900233L (en) Low dose benazepril/thiazide diuretic composition
CA2431125C (fr) Methode de traitement de la dyserection
BG107264A (en) Antihypertensive means and their administration
JPS6391326A (ja) 高血圧治療用医薬組成物
CN101002766A (zh) 血管紧张素ⅱ拮抗剂与血管紧张素ⅰ转换酶抑制剂的药物结合物
HK1104976A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued